Companies › Sichuan Kelun-Biotech Biopharmaceutical
17 active drug programs in 44 registered trials: 19 Phase 2, 15 Phase 1, 10 Phase 3; Oncology, Immunology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer … | Nov 2026 |
| Trastuzumab Botidotin (A166) Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor | ERBB2, Tubulin | Phase 3 | HER2-positive Breast Cancer; Her 2 Positive Breast Cancer | Nov 2026 |
| KL-A167 | – | Phase 3 | Nasopharyngeal Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung Cancer | Dec 2026 |
| Eribulin (SKB264) Tubulin inhibitor | Tubulin | Phase 3 | Triple Negative Breast Cancer | Jun 2027 |
| SKB571 MET inhibitor | MET | Phase 2 | Non-small Lung Cancer; Gastrointestinal Tumors; Lung Cancer (Non-Small Cell); HNSCC … | Dec 2026 |
| SKB518 Unclear - code-named investigational drug | – | Phase 2 | Lung Carcinoma; Advanced Gynecological Malignancies; Advanced Solid Tumors | Feb 2027 |
| SKB500 | – | Phase 2 | Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Advanced Solid Tumors | Jul 2027 |
| KL590586 RET inhibitor | RET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| SKB445 for injection | – | Phase 1 | Advanced Solid Tumors | Dec 2026 |
| SKB107 Lutetium-177 DOTA-conjugated radionuclide targeting bone metastases | – | Phase 1 | Metastatic Solid Tumors | Oct 2027 |
| SKB575 (HBM7575) | – | Phase 1 | Atopic Dermatitis; Asthma (Diagnosis) | Dec 2027 |
| SKB315 for injection anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| SKB565 | – | Phase 1 | Advanced Solid Tumors | Mar 2029 |
| SKB118 Injection | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| MK-6204 (SKB535) for Injection | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| SKB103 for injection | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| SKB105 for injection Antibody-drug conjugate (ADC) | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05870319 | Sacituzumab Govitecan (SKB264) | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jul 2024 |
| NCT06428331 | SKB518 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2026 |
| NCT06448312 | Sacituzumab Govitecan (SKB264) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Nov 2026 |
| NCT06968585 | Trastuzumab Botidotin (A166) | Phase 3 | HER2-positive Breast Cancer | Oncology | Nov 2026 |
| NCT06725381 | SKB571 | Phase 1 | Solid Malignancies | Oncology | Dec 2026 |
| NCT05351788 | KL-A167 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06711900 | Sacituzumab Govitecan (SKB264) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05351788 | Sacituzumab Govitecan (SKB264) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05631262 | Sacituzumab Govitecan (SKB264) | Phase 2 | Selected Subjects With Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06826040 | SKB445 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
| NCT06081959 | Sacituzumab Govitecan (SKB264) | Phase 3 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT05265091 | KL590586 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07019675 | SKB518 | Phase 2 | Lung Carcinoma | Oncology | Feb 2027 |
| NCT06279364 | Sacituzumab Govitecan (SKB264) | Phase 3 | Triple Negative Breast Cancer | Oncology | Apr 2027 |
| NCT06670196 | Sacituzumab Govitecan (SKB264) | Phase 3 | Non-Small Cell Lung Cancer | Oncology | May 2027 |
| NCT05347134 | Eribulin (SKB264) | Phase 3 | Triple Negative Breast Cancer | Oncology | Jun 2027 |
| NCT07308106 | SKB571 | Phase 2 | Non-small Lung Cancer | Oncology | Jun 2027 |
| NCT07071337 | Sacituzumab Govitecan (SKB264) | Phase 3 | Metastatic Breast Cancer | Oncology | Jul 2027 |
| NCT06736327 | SKB500 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2027 |
| NCT07564466 | SKB571 | Phase 2 | Gastrointestinal Tumors | Oncology | Aug 2027 |
| NCT07329322 | Sacituzumab Govitecan (SKB264) | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT07299825 | Trastuzumab Botidotin (A166) | Phase 2 | Her 2 Positive Breast Cancer | Oncology | Sep 2027 |
| NCT07087197 | SKB107 | Phase 1 | Metastatic Solid Tumors | Oncology | Oct 2027 |
| NCT05294172 | KL-A167 | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2027 |
| NCT07448922 | SKB518 | Phase 2 | Advanced Gynecological Malignancies | Oncology | Dec 2027 |
| NCT07488065 | SKB575 (HBM7575) | Phase 1 | Atopic Dermatitis | Immunology | Dec 2027 |
| NCT07341100 | Sacituzumab Govitecan (SKB264) | Phase 2 | Ovarian Epithelial Cancer | Oncology | Jan 2028 |
| NCT07230405 | SKB571 | Phase 2 | Lung Cancer (Non-Small Cell) | Oncology | Jan 2028 |
| NCT07324629 | Sacituzumab Govitecan (SKB264) | Phase 2 | Thymic Carcinoma | Oncology | Apr 2028 |
| NCT05367635 | SKB315 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2028 |
| NCT07732023 | SKB575 (HBM7575) | Phase 1 | Asthma (Diagnosis) | Respiratory | Jul 2028 |
| NCT07697586 | Sacituzumab Govitecan (SKB264) | Phase 2 | NSCLC | Oncology | Aug 2028 |
| NCT07697586 | Sacituzumab Govitecan (SKB264) | Phase 2 | NSCLC | Oncology | Aug 2028 |
| NCT07668154 | SKB571 | Phase 2 | HNSCC | Oncology | Sep 2028 |
| NCT07622186 | SKB571 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07296809 | SKB500 | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07700667 | SKB500 | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2028 |
| NCT07296809 | KL-A167 | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07545265 | SKB565 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2029 |
| NCT07586943 | SKB118 Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
| NCT07586943 | Sacituzumab Govitecan (SKB264) | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
| NCT07459998 | SKB103 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
| NCT06726369 | MK-6204 (SKB535) for Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
| NCT07380386 | SKB105 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
Sichuan Baili Pharmaceutical Shanghai Hengrui Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical DualityBio Shenyang Sunshine Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.